PUBLICATION/ISSUE REVIEW COMPLETE
on 11 Dec 2024
Last Applicant/ Owned by
800 Boylston Street, STE 2222
Boston
MA
02199
Serial Number
98072031 filed on 05th Jul 2023
Registration Number
N/A
Correspondent Address
Ava R. Shelby
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
NVELOP
medical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, scientific research and medical research in the field of gene editing technology featuring gene-edit Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
medical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, scientific research and medical research in the field of gene editing technology featuring gene-editing and protein delivery; pharmaceutical research services; pharmaceutical drug development services; medical and scientific research for the treatment of genetic diseases and disorders
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
pharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate delivery of pharmaceuticals, namely, drug delivery agents consisting of particles in the nature of virus-like particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles in the nature of virus-like particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human organs; cell and gene therapy products for increasing protein expression in cells, namely, engineered virus-like particles; pharmaceutical and biological preparations for delivering proteins into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; pharmaceutical and biological preparations for delivering therapeutic proteins for treatment of cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98072031
Mark Type
No Service Mark
Attorney Docket Number
No 62697-TM1001
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 06th Dec 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 26th Nov 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 25th Nov 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 25th Nov 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 01st Nov 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| 01st Nov 2024 | PRIORITY ACTION WRITTEN |
| 01st Nov 2024 | PRIORITY ACTION E-MAILED |
| 07th Oct 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| 07th Oct 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| 13th Jul 2024 | FINAL REFUSAL WRITTEN |